Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts. The company reported positive six-month results from its first-in-human (FIH) study, which support advancement to Group Two clinical surgeries.
Six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes, with the study achieving its primary objectives related to safety, lens delivery and distance vision correction. Anecdotally, patients reported meaningful improvements in vision and quality of life, including one individual previously considered legally blind who is now qualified to drive.
Ocumetics has completed development of its next-generation solid-state accommodating intraocular lens, incorporating significant advancements in manufacturability, surgical handling, long-term reliability and accommodative performance. The redesigned lens features a simplified one-piece design that eliminates internal interface materials and contains no air, water or oil. Manufacturing of the redesigned lens has commenced with the company's German manufacturing partner, Amiplant GmbH. Upcoming activities include finalization of manufacturing, product verification, sterilization, product packaging and release of clinical inventory ahead of planned Q3 2026 clinical surgeries.
The company has successfully completed all regulatory requirements necessary to proceed to Group Two patient enrollment. Working closely with clinical investigators, ethics committees and regulatory consultants, Ocumetics has completed the regulatory processes required to advance the study. Group Two surgeries remain on schedule for Q3 2026 in Mexico City under the leadership of Principal Investigator Dr. Raphael Vasquez.
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, Ocumetics has launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities. Proceeds are expected to be used to complete Group Two FIH surgeries, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging activities, advance regulatory and quality assurance programs, and continue strategic partnership and commercialization initiatives.
Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities. Based on encouraging feedback received during meetings, several organizations have expressed interest in reviewing additional clinical data following completion of Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026 following the availability of Group Two one-month patient results.
Management believes the continued level of investor engagement reflects growing recognition of the company's clinical progress and long-term commercial opportunity. With positive six-month clinical data, completion of the next-generation lens design, manufacturing underway, regulatory milestones achieved and strategic commercialization discussions continuing with leading global ophthalmic companies, Ocumetics believes it is well positioned to execute the next phase of its clinical development strategy.
